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Abstract
Our understanding of genes that cause skeletal muscle disease has increased tremendously over the past three
decades. Advances in approaches to genetics and genomics have aided in the identification of new pathogenic
mechanisms in rare genetic disorders and have opened up new avenues for therapeutic interventions by
identification of new molecular pathways in muscle disease. Recent studies have identified mutations of several
Kelch proteins in skeletal muscle disorders. The Kelch superfamily is one of the largest evolutionary conserved gene
families. The 66 known family members all possess a Kelch-repeat containing domain and are implicated in diverse
biological functions. In skeletal muscle development, several Kelch family members regulate the processes of
proliferation and/or differentiation resulting in normal functioning of mature muscles. Importantly, many Kelch
proteins function as substrate-specific adaptors for Cullin E3 ubiquitin ligase (Cul3), a core component of the
ubiquitin-proteasome system to regulate the protein turnover. This review discusses the emerging roles of Kelch
proteins in skeletal muscle function and disease.
Keywords: Kelch, BTB, BACK, Nemaline myopathy, Dystrophy, Congenital myopathy, Cul3, Ubiquitination,
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Review
Skeletal muscle development is a highly coordinated
process that involves the myogenesis and differentiation
of primary myoblasts, and their integrated growth and
development into a mature functional organ [1-4]. Con-
sequently, mutations of a large number of proteins asso-
ciated with development and/or maintenance of skeletal
muscle result in disease states. Over the past three
decades, tremendous progress has been made in eluci-
dating the genetic basis of muscle diseases. Primary
inherited diseases of skeletal muscle include the muscu-
lar dystrophies and the non-dystrophic congenital myop-
athies [5-8]. Muscular dystrophies are characterized by
myofiber degeneration with repeated rounds of regener-
ation that ultimately lead to an end-stage process typi-
fied by fibrosis and replacement by adipose tissue [9,10].
In contrast, non-dystrophic myopathies exhibit little nec-
rotic or regenerative changes, but muscle biopsies often
display characteristic structural changes such as central
cores, nemaline rods, central nuclei, various intracytoplas-
mic inclusions, or fiber type disproportion, and so on
[10,11]. Collectively, these diseases are both phenotypically
and clinically heterogeneous. Gene discovery in muscle
diseases is currently skyrocketing due to the use of next-
generation sequencing approaches [12-19]. The discovery
of new genes is not only crucial for improving diagnostics
for these highly heterogeneous muscular disorders, but
also is critical for identifying new molecular pathways
that may serve as potential therapeutic targets. Recent
gene discoveries have identified mutations in Kelch pro-
tein genes as the cause of muscle diseases in humans
[14,20-22]. Kelch proteins belong to the Kelch superfamily
that consists of a large number of structurally and func-
tionally diverse proteins characterized by the presence of a
Kelch-repeat domain [23,24]. Kelch family members are
involved in a number of cellular and molecular processes
such as cell migration, cytoskeletal arrangement, regula-
tion of cell morphology, protein degradation, and gene ex-
pression [25-31]. This review summarizes our emerging
understanding of the various roles of Kelch proteins in
skeletal muscle development and disease (Tables 1 and 2).
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The Kelch superfamily includes 66 genes, of which 63
are protein-coding whereas three are non-coding genes.
The Kelch protein family is primarily classified into
KLHL, KBTBD, and KLHDC subfamilies that differ in
the types and numbers of their protein domains (http://
www.genenames.org/) (Figure 1A). A prototypic member
of the Kelch family contains an N-terminal BTB/POZ
domain, a BACK domain, and two to eight C-terminal
Kelch motifs [61]. KLHL subfamily members contain all
of these domains whereas the KBTBD subfamily mem-
bers typically lack the BACK domain [24]. KLHDC
subfamily members do not contain either BTB or BACK
domains (Figure 1B and 1C). However, some KLHDC
subfamily members do contain alternative domains,
such as the transmembrane (KLHDC7A), Glycine rich
(KLHDC10), Lish and CTLH (MKLN1) domains, in
addition to traditional Kelch repeats.
A phylogenetic analysis of human Kelch family pro-
teins shows that most members within each subfamily
largely cluster together with the KLHDC subfamily, that
lacks BTB and BACK domains, apparently having di-
verged first (Figure 2A). However, several members are
clustered with other subfamilies suggesting that some
gain or loss of BTB or BACK domains may have occa-
sionally occurred at later stages of evolution. Kelch pro-
teins bind to specific substrates through their Kelch
domains. An amino acid alignment of only the Kelch
repeat regions shows that proteins involved in similar
disease processes are clustered together (for example,
KLHL40, KLHL41, and KBTBD13, all of which cause
nemaline myopathy) (Figure 2B). This suggests that
Table 1 Kelch family proteins in skeletal muscle development
Gene Protein Function Expression
KLHL19 KLHL19, KEAP1 Oxidative stress and insulin signaling in muscle cells [32] Ubiquitous [33]
KLHL31 KLHL31 Skeletal and cardiac muscle myogenesis [29,34] Skeletal muscle, heart (low levels in
brain, kidney, and liver) [29]
KLHL39 KLHL39, IVNS1ABP Protection against drug-induced cardiomyopathy [35] Ubiquitous [36]
KLHL40 (KBTBD5) KLHL40 Skeletal muscle differentiation [14,37] Skeletal muscle [14]
KLHL41 (KBTBD10,KRP1) KLHL41, Sarcosin Skeletal muscle differentiation and myofibril assembly [22,38,39] Skeletal muscle, lungs [22]
MKLN1 MKLN1, Muskelin Muscle cell adhesion and extracellular communication [40] Skeletal muscle, brain [40,41]
KLHDC1 KLHDC1 Muscle cell migration and differentiation [42,43] Skeletal muscle [42]
KLHDC2 KLHDC2 Muscle cell migration and differentiation [42,43] Skeletal muscle [42]
Table 2 Kelch family proteins in human diseases
Gene Function Expression
Neuromuscular diseases
KLHL1 Spinocerebellar ataxia type 8 [44] Brain, prostate, small intestine, colon [44]
KLHL9 Distal myopathy [20] Ubiquitous [20]
KLHL16 (GAN) Giant axonal neuropathy [45] Brain, skeletal muscle, heart, kidney, liver [46]
KLHL40 (KBTBD5) Severe nemaline myopathy with fetal akinesia [14,37] Skeletal muscle [14]
KLHL41 (KBTBD10) Nemaline myopathy [22,38,39] Skeletal muscle, lungs [22]
KBTBD13 Nemaline myopathy with cores [21] Skeletal muscle, lungs, heart [21]
Cancer
KLHL6 Chronic lymphocytic leukemia [47] Lymphocytes (unknown in other tissues) [48]
KLHL19 (KEAP1) Pulmonary papillary adenocarcinoma [49] Ubiquitous [50]
KLHL20 Prostate cancer progression [51] Ubiquitous [52]
KLHL37 (ENC1) Brain tumors [53] Brain (unknown in other tissues) [54]
KLHDC8B Hodgkin’s lymphoma [55] Unknown
Other Inherited Diseases
KLHL3 Pseudohypoalsosteronism type II [56] Cerebellum, kidney, spinal cord, heart,
lung, placenta, testis, arota [56]
KLHL7 Autosomal dominant retinitis pigmentosa [57] Ubiquitous [57]
KLHL10 Oligozoospermia [58,59] Testis [60]
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regulating similar biological processes through interac-
tions with shared or related binding partners. Under
this model, functional differences between these related
Kelch family members will likely derive from variation in
other domains of the proteins.
BTB/POZ domain
The BTB/POZ domain derives its name from the
Drosophila Bric-a-brac, Tramtrac, and Broad complex due
to sequence homology [62,63]. As the DNA poxvirus in
which this domain was first identified also showed some
similarity to zinc finger proteins, this domain was concur-
rently named the POZ (Poxvirus and Zinc finger) domain.
BTB domains are mainly involved in facilitating self-
oligomerization or mediating protein-protein interactions
with other proteins [64,65]. Despite the similar secondary
structures and shared organization of BTB proteins, their
primary sequences are not well conserved. This sequence
variability between BTB proteins contributes to differen-
tial protein-protein interactions and results in different
functional roles. BTB domains are also present in other
non Kelch-repeat containing proteins. The major differ-
ence lies in the protein interactors of BTB domains in
Kelch versus non-Kelch proteins. In the Kelch family,
the most important known interactive role of the BTB
domain is to act as an adaptor between E3 ubiquitin li-
gases and Kelch domains in order to form active ubi-
quitination complexes [66-68]. In non-Kelch families of
proteins, BTB protein-regulated interactions typically in-
volve recruitment of co-activators or repressors to tran-
scription complexes. In addition, these interacting proteins
are also involved in cytoskeletal arrangement and ion con-
ductance [69-72].
BACK domain
The BACK domains found in KLHL subfamily members
are the most conserved domain of the Kelch family and are
present between the N-terminal BTB and C-terminal Kelch
domains. BACK domains contain an N-terminal conserved
Asn-Cys-Leu-Gly-Ile motif and a Val-Arg-[Leu/Met/Phe]-
Pro-Leu-Leu sequence, two arginines, four glutamic acids,
and several hydrophobic positions causing them to be
hydrophobic in nature [61]. The true role of the BACK do-
main is not known, but it is predicted to participate in
BTB-E3 ubiquitin ligase complex formation [61]. Evidence
for the functional significance of BACK domains comes
from recent studies where missense mutations in this do-
main in KLHL40 and KLHL41 are pathogenic in human
patients affected with nemaline myopathy [14,22].
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Figure 1 The Kelch Superfamily. (A) The Kelch family consists of 63 proteins that are subclassified in to KLHL, KBTBD and KLHDC subfamilies.
(B) Structure of Kelch domain of rat KLHL41 (PDB code 2WOZ) comprising six repeats that form the complete Kelch domain. The structure was
generated using PyMOL (www.pymol.org). (C) Prototype members of different subfamilies showing different domain organization. KLHL proteins
have an N-terminal BTB/POZ, a BACK and C-terminal Kelch repeats. KBTBD proteins contain an N-terminal BTB domain and Kelch repeats. The
BACK domain is normally absent in KBTBD proteins. KLHDC proteins lack both BTB/POZ and BACK domains and contain either Kelch repeats
alone or with other domains such as transmembrane (for example, KLHDC7A), Glycine rich (for example, KLHDC10), or Lish and CTLH domains
(for example, MKLN1).
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KLHL19 (NP_987096.1) **
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KLHL20 (NP_055273.2) **
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KLHL36 (NP_079007.2)
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KLHL9 (NP_061335.1) *
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Figure 2 Phylogenetic analysis showing relationships between human Kelch protein family members. (A) Phylogenetic tree of full-length
amino acid sequences of human proteins were aligned. (B) Phylogenetic tree of amino acid sequences of Kelch domains. Phylogenetic trees were
constructed by maximum-likelihood method using BLOSUM matrix in MEGA 6.06. Reference sequences used for alignments are indicated at right
of each protein name. Blue highlighting indicates KBTBD subfamily members; green indicates KLHDC subfamily members. *, proteins involved in
neuromuscular diseases; **, family members implicated in cancer; #, proteins whose defects cause other inherited diseases (Table 2). Scale bars
indicate relative distances and represent the degree of differences between the sequences.
Gupta and Beggs Skeletal Muscle 2014, 4:11 Page 4 of 12
http://www.skeletalmusclejournal.com/content/4/1/11Kelch domain
Kelch motifs range from 44 to 56 amino acids in length
and are usually arranged in a series of five to seven repeats
in most of the family members [23]. The signature motifs
in each Kelch repeat are a series of four hydrophobic
amino acids followed by glycine doublet, a conserved tyro-
sine, and a conserved tryptophan. Each Kelch repeat folds
into four twisted antiparallel β-strands connected by
intrablade loops to form a single blade of a β-propeller
(Figure 1B). A C-terminal strand closure mechanism links
the first and last blades to complete the propeller. Kelch
β-propellers primarily function as scaffolds for protein-
protein interactions. Despite the shared tertiary structure,
there is little primary sequence identity between one Kelch
repeat and another, suggesting a wide diversity of interact-
ing partners across the Kelch superfamily. In nemaline my-
opathy, all pathogenic KBTBD13 mutations identified to
date in human patients were found in the Kelch repeats
[21]. Similarly, mutations in Kelch repeats of both KLHL40
or KLHL41 also result in nemaline myopathy [14,22].
Kelch proteins in skeletal muscle diseases
KLHL9
The first Kelch protein defect reported in a primary skel-
etal muscle disease was of KLHL9, resulting in an early
onset autosomal dominant form of distal myopathy [20].
Distal myopathies are a heterogeneous group of muscle
diseases characterized by progressive muscular atrophy
and weakness, beginning in distal (hence the name) and
progressing to proximal limb muscles [73]. By linkage
analysis and subsequence candidate sequencing, Cirak
et al. identified a p.Leu95Phe missense change in the
N-Terminal BTB domain of KLHL9 in several affected
members of a single large German family with a domin-
ant form of distal myopathy [20]. Leucine is conserved
at this position in other vertebrates, and molecular mod-
eling predicted that the change to phenylalanine would
affect BTB domain conformation and likely disrupt the
protein-protein interactions with Cul3 ubiquitin ligase.
Cell culture studies subsequently showed that wild-type
KLHL9 interacted with Cul3 ubiquitin ligase whereas
the p.Leu95Phe mutation disrupted the KLHL9-Cul3
interaction [20,74]. The Kelch family members act as
substrate-recognizing adaptors of the Cul3 ubiquitina-
tion complex, which targets specific substrates for ubi-
quitination and subsequent degradation by proteasomal
pathways. While experimental evidence for KLHL9 as a
regulator of ubiquitination in skeletal muscles is still
lacking, one potential substrate for KLHL9 action is pos-
tulated to be Aurora B kinase [20]. Previous studies have
shown that KLHL9 targets this kinase during mitotic
progression and cytokinesis [75]. Aurora B kinase is a
regulator of assembly and disassembly of type III inter-
mediate filaments including vimentin, desmin, and type
IV neurofilaments. Therefore, a mis-regulation of Aurora
B Kinase function in KLHL9 deficiency is postulated to
affect normal skeletal muscle function [76].
KBTBD13
KBTBD13 is a member of the KBTBD subfamily of
Kelch proteins that contains a BTB domain and Kelch
repeats but lacks a BACK domain. KBTBD13 mutations
result in an autosomal dominant form of nemaline my-
opathy associated with cores in affected patients [21].
Clinically, patients with KBTBD13 mutations exhibit
poor exercise tolerance, gait abnormality, and progres-
sive weakness of the neck and proximal limb muscles.
The peculiar clinical feature specific to KBTBD13 pa-
tients that is not seen in other forms of congenital my-
opathies is a characteristic slowness of movement, where
patients are unable to run and correct themselves from
falling over. Moreover, skeletal muscles of patients with
KBTBD13 mutations exhibit cores that lack oxidative
enzymatic activity and show predominance as well
as hypertrophy of type 1 (slow) myofibers [21]. The
localization of KBTBD13 in myofibers is not clear.
Localization studies have shown that KBTBD13 does
not co-localize with α-actin (thin filament protein) or
α-actinin (a Z-line marker), suggesting a different
localization and mechanism of action than previously
known proteins in nemaline myopathy, which primarily
localize to thin filaments [21]. All known pathogenic
mutations in KBTBD13 are localized in the Kelch re-
peats of the protein and are predicted to damage the
β-propeller blades. KBTBD13 forms a complex with
Cul3 ubiquitin ligase through its N-terminal BTB do-
main and this interaction is required for the formation
of a functional Cul3 ubiquitin ligase complex, suggesting
that the pathogenic mechanism in KBTBD13-related
nemaline myopathy may involve dysregulation of cellular
protein ubiquitination [66].
KLHL40
KLHL40 mutations have been recently identified as a
cause of nemaline myopathy in a severe form of the
disease [14]. KLHL40 belongs to the KLHL subfamily
of Kelch proteins that contain an N-terminal BTB do-
main, a BACK domain, and five Kelch repeats on the
C-terminal end. Recessive mutations in KLHL40 are as-
sociated with fetal akinesia or hypokinesia during the
prenatal period, respiratory failure, and swallowing diffi-
culty at birth, as well as contractures, fractures, and
dysmorphic features that in many cases are associated
with early death. A significant number of patients with
KLHL40 mutations (approximately 17%) also exhibit
ophthalmoparesis that is usually not present in other
genetic subtypes of nemaline myopathy. Moreover,
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KLHL40 patients that is not commonly seen in other
forms of nemaline and other congenital myopathies.
Mutations of KLHL40 have been found in exons encod-
ing all domains of the protein with a majority of the mu-
tations seen in the Kelch repeats, including a founder
mutation (p.Glu528Lys) present in Japanese, Turkish,
and Kurdish populations. Both truncating as well as mis-
sense mutations are seen in KLHL40. Knockdown of
KLHL40 orthologues in zebrafish results in sarcomeric
abnormalities and impaired locomotion similar to hu-
man patients, providing further evidence that KLHL40 is
the disease-causing gene in nemaline myopathy [14].
Murine Klhl40 protein is localized at triads along with
the sarcoplasmic reticulum (SR) marker Ryr1 [22].
KLHL40 interacts with CUL3 ubiquitin ligase via the
N-terminal BTB domain and forms a protein complex,
the functional significance of which remains to be unrav-
eled [68]. Recent work has also shown that Klhl40
promoter is a direct target of myoD and is crucial for
muscle cell differentiation [22,37].
KLHL41
KLHL41 is the most recent member of the Kelch family
to be implicated in muscle disease. Unlike KLHL9 and
KBTBD13 mutations that cause a dominant form of the
disease, mutations in KLHL41, like KLHL40, result in
an autosomal recessive form of nemaline myopathy.
Genetic analysis of five unrelated families has shown
that KLHL41 mutations appear to follow a genotype-
phenotype correlation. Mutations that led to truncated
proteins resulted in a severe form of the disease with
fetal akinesia, a lack of antigravity movement, arthrogry-
posis, and dislocation of the hip and knees. These pa-
tients died within the first few months of life due to
respiratory insufficiency. Missense changes resulted in a
mild or intermediate form of the disease with impaired
motor functions and survival into late childhood and/or
early adulthood. KLHL41 localizes in the perinuclear
area and over (but not within) I bands, in association
with the terminal cisternae and longitudinal vesicles of
the SR membranes present in the I-band area at the
triadic regions. As most of the previously known NM
proteins are components of sarcomeric thin filaments,
the unique localization of KLHL41, as well as non-
sarcomeric localization of KLHL40 in association with
the triads, suggests the involvement of new pathophysio-
logical mechanisms for nemaline myopathy [77]. Knock-
down of KLHL41 in zebrafish resulted in skeletal muscle
myopathy with disorganized and thinner myofibers as
well as reduced motor function in comparison to wild-
type zebrafish. Interestingly, morphant fish also exhib-
ited numerous electron dense structures in skeletal
muscle, reminiscent of small or nascent nemaline bodies,
in addition to Z-line thickening as seen in human nema-
line myopathy patients.
Previous studies have shown that KLHL41 interacts
with Cul3 ubiquitin ligase to form functional ubiquitina-
tion complexes with proteins targeted for degradation
[78]. The identification of protein substrates targeted by
the KLHL41-Cul3 ubiquitin complex is not known.
KLHL41 interacts with nebulin [79] and co-localizes
with actin [80], mutations of which cause approximately
65% to 70% of all known mutations in patients affected
with nemaline myopathy [81]. The high degree of se-
quence similarity between Kelch repeats of KBTBD13,
KLHL40, and KLHL41 suggests that they may share
identical or closely related binding partners whose dys-
regulation leads to nemaline myopathy through a com-
mon final pathway and implicates a critical role for
BTB-Kelch family members in the maintenance of sarco-
meric integrity in skeletal muscle.
Kelch proteins in skeletal muscle development
Members of the Kelch family are known to be involved
in multiple biological processes such as migration, cyto-
skeletal arrangement, regulation of cell morphology,
myofibril assembly, protein degradation, and gene ex-
pression [25,27,45,80,82,83]. Several Kelch proteins asso-
ciate with the actin cytoskeleton via the β-propeller
module, and these associations are important for func-
tional roles of these proteins [84,85]. Other Kelch proteins
affect the organization of cytoskeletal, plasma membrane,
or organelle structures but do not bind directly to or
co-localize with actin.
In skeletal muscle, many Kelch proteins are known to
regulate the proliferation as well as differentiation of
muscle cells. KLHL41 is highly expressed in myoblasts
during early muscle differentiation [86]. Knockdown as
well as overexpression of KLHL41 in C2C12 cells inhib-
ited myoblast differentiation, suggesting a role in cell
cycle exit and the promotion of differentiation [38].
Knockdown of KLHL41 in cultured cardiomyocytes
affected lateral fusion of myofibrils resulting in thin
myofibrils [39]. In developing chicken and zebrafish
embryos, KLHL31 is specifically expressed in early heart
and in developing myoblasts shortly after their commit-
ment to this fate, signifying an important role during
skeletal muscle and cardiac myogenesis [29]. The ex-
pression of KLHL31 is initiated just after MyoD in devel-
oping skeletal muscles and this expression persisted in
later stages of development implying the possible in-
volvement of KLHL31 in the early phases of myogenic
commitment and during later muscle differentiation
[34]. KLHL31 acts as a transcriptional repressor in the
MAPK/JNK signaling pathway in mouse cardiomyocytes.
In skeletal muscle cells, overexpression of KLHDC2 ren-
dered these cells unable to respond to chemoattractants
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adherence [26]. Additionally, myoblasts overexpressing
KLHDC2 failed to differentiate into mature myotubes.
KLHDC2 also regulates transcription processes by
inducing expression of the leucine zipper transcription
factor (LZIP) in muscle cells. KLHDC1 is a paralogue of
KLHDC2 and shares 50% similarity with KLHDC2. Simi-
lar to KLHDC2, the highest expression of KLHDC1 is
observed in skeletal muscles [42]. However, the func-
tional roles of KLHDC1 remain unknown. Muskelin
(MKLN1, a KLHDC subfamily member) was identified
in an expression cloning screen for molecules that pro-
moted cell adhesion to the extracellular matrix compo-
nent thrombospondin 1. Overexpression or antisense
depletion of muskelin in mouse skeletal myoblasts corre-
lates with altered organization of fascin microspike-
based adhesive contacts and a redistribution of focal
contact in TSP-1 adherent cells, yet has modest effects
on actin organization in cells adherent on fibronectin
[40]. These results suggest that muskelin functions at
a node point in the integration of cell responses to
complex extracellular matrix. As most of muskelin is
cytoplasmic, its effects on matrix contacts are thought to
be mediated indirectly. The requirement of Kelch pro-
teins in cell morphology comes from yeast-based studies
where mutations in Kelch proteins resulted in cell fusion
defects [87]. The emerging roles of Kelch proteins in
metabolic pathways come from a recent study where
Keap1 (Klhl19) knockout mice exhibited a significant re-
duction in insulin signaling pathway gene expression in
skeletal muscles [32,88,89]. Keap1 also regulates redox sig-
naling, as increased oxidative stress thought to be associ-
ated with its dysregulation is observed in sedentary elderly
people [89]. Nd1-L (KLHL39)i sa na c t i nb i n d i n gp r o t e i n
expressed in high levels in heart that protects against
doxorubicin-induced cardiomyopathy in mice [35].
Molecular pathways regulated by Kelch proteins
Detailed studies on molecular functions of Kelch pro-
teins are still largely lacking except with regard to their
roles as substrate specific adaptors in the ubiquitination
pathways, thereby regulating diverse cellular processes
[21,28,90-94]. Skeletal muscle proteins are especially
prone to wear and tear as they are the primary force
generating mechanism in skeletal muscle. A quality
control check, by removal of damaged proteins and co-
ordinated turnover, is performed by many proteolytic
systems in skeletal muscles: the caspase and calpain sys-
tems of partially muscle-specific proteases; the ubiquitin
proteasome system (UPS) which degrades polyubiquiti-
nated proteins via the 26S proteasome; and the autophaghy
pathway which removes proteins by inclusion in autophagic/
lysosomal vesicles [95-104]. Kelch proteins function by
acting as substrate specific adaptors for the Cullin3-
dependent E3 ubiquitination ligase complex during protein
ubiquitination [93,105,106].
Ubiquitination is a multistep process in which an E1
ubiquitination activating enzyme transfers ubiquitin to
an E2 ubiquitin-conjugating enzyme. The final step of
this process is the ligation of ubiquitin to the substrate,
catalyzed by an E3 ubiquitin protein ligase [107-109]. As
the stability of a large number of proteins is controlled
by the ubiquitin system, it is crucial to determine how
the cell achieves sufficient diversity among E3s so that
each one selectively recognizes only one or a few sub-
strates in the sea of cellular proteins present at any time.
Several hundreds of such E3 ligases are described,
some of which are clearly specific to skeletal muscles
[110,111]. One subgroup of E3 ligases are the ubiqui-
tously expressed cullins that do not bind to their sub-
strates directly, but rely on an array of adaptor proteins.
There are seven cullin genes known in mammals
(CUL1-CUL3, CUL4a, CUL4b, CUL5, and CUL7), but
only CUL3 interacts with the BTB-Kelch proteins [112].
Thus, BTB-domain proteins serve as the substrate spe-
cific adaptors of CUL3-based E3 ubiquitin ligases [113].
The crucial requirement of CUL3 function is evident
from Cul3 null mice that exhibit embryonic lethality.
In particular, Cul3 null homozygous mice exhibit abnor-
mal cycling of cells in extraembryonic membranes, re-
duced size, abnormal gastrulation and trophoblast cells,
absence of an amnion, and death by embryonic day 7.5
[114]. In humans, dominant CUL3 mutations are associ-
ated with pseudohypoaldosteronism type II, a genetic
disorder causing hypertension, hyperkalemia, and meta-
bolic acidosis [92]. Even though CUL3 is ubiquitously
expressed, the functional specificity of CUL3 in different
spatial and developmental contexts is exhibited through
protein-protein interaction with different Kelch proteins.
This may in part be regulated by tissue specific expres-
sion, and substrate specificity of the different Kelch
protein-binding partners. KLHL40 and KLHL41 are pri-
marily expressed in skeletal (with low expression in cardiac)
muscles. In skeletal muscles, deficiency of these proteins
and thereby a perturbation of Cul3 ubiquitin complex
formation to regulate the protein turnover of specific
substrates may lead to skeletal muscle diseases.
The regulation of ubiquitination by Kelch proteins in
skeletal muscles has been investigated in the context
of disease. Kelch proteins such as KLHL9, KBTBD13,
KLHL40, and KLHL41 that cause skeletal muscle disorders,
each form protein complexes with CUL3 [20,66,68,78]. The
functional significance of these interactions has been
shown by several studies, as Cul3-KLHL41 and Cul3-
KBTBD13 complexes are able to perform in vitro ubiquiti-
nation in the presence of other members of the functional
ubiquitination complex [66,78]. Moreover, in distal myop-
athy, the interaction of mutant KLHL9 with Cul3 is highly
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turn affect the ubiquitination of cellular proteins [20].
Identifying the protein interactors of each of these Kelch
proteins in skeletal muscle will provide further insight into
disease mechanisms. A study of the skeletal muscle inter-
actome showed that KLHL41 interacts with TCAP, ENO3,
and SGCG, three proteins encoded by genes mutated in
limb-girdle muscular dystrophy type 2G, metabolic myop-
athy, and limb-girdle muscular dystrophy type 2C, respect-
ively [79]. This points toward the potential regulatory
roles of Kelch proteins and/or ubiquitination pathways in
other muscle diseases as well [79,115-117]. KLHL41 also
interacts with nebulin, a known causative gene of nema-
line myopathy, by protein-protein interactions and is
co-localized with actin at the tips of pseudopodia in fibro-
blasts. These data suggest that KLHL41 and other disease-
causing Kelch proteins KLHL40, KBTBD13, and KLHL9
may contribute to disease pathogenesis by regulating the
protein turnover of nebulin, actin, and other important
skeletal muscle proteins that are required for normal
functioning of skeletal muscle (Figure 3). In the absence
of Kelch proteins, disturbance of this protein turnover
process and subsequent overabundance of damaged sarco-
meric proteins may result in disease states in affected
muscles (Figure 3). In addition to protein degradation,
ubiquitination has non-degradative roles such as modula-
tion of protein activity, interaction, and sub-cellular
localization of proteins [118,119], so it may be that some
of these Kelch proteins actually promote the stability of
their binding partners. Future studies will help us to better
understand these processes in the context of skeletal
muscle development and diseases.
Kelch proteins in other human diseases
A number of Kelch proteins play important roles in a
variety of human diseases, including cancer and neuro-
logical disorders [55,120-122] (Table 2). Mutations of
KLHL6, KLHL19, KLHL20, and KLHL37 are associated
with various forms of cancers [47,49,51,53]. Whole ex-
ome sequencing in a rare genetic disorder, pseudohy-
poalsosteronism type II, involving hypertension,
hyperkalemia, and metabolic acidosis, recently identi-
fied mutations in the KLHL3 gene [56,92]. KLHL3 mu-
tations are either recessive or dominant in nature. The
recessive mutations are distributed throughout the
encoded protein, whereas dominant mutations were
localized in the cullin binding sites, likely impairing the
formation of active Cul3 complexes. Linkage analysis
and mutation screening in 502 retinopathy probands
identified KLHL7 as a cause of autosomal dominant
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A
Figure 3 Kelch proteins act as a substrate specific adaptors for E3-ubiquitinin protein complex. (A) Cullin3 complex is Nedd8 (N8)
modified and recruits E2-bound ubiquitin through RING-finger protein Rbx1. The assembly of a functional ubiquitination complex requires the
binding of Cul3-E2 complex to substrate specific Kelch adaptor proteins. Cul3 directly binds to N-terminal BTB domain of Kelch protein and this
E3-ubiquitination complex interacts with substrates (for example, S1, S2, S3) by C-terminal Kelch-repeat containing domains of Kelch proteins,
causing ubiquitination of the target proteins and subsequent degradation (or stabilization and so on) by the proteasome system. This results in
normal protein turnover of proteins required for normal functioning of muscle resulting in healthy skeletal muscles. (B) The deficiency of Kelch
proteins (such as disease causing KLHL9, KLHL40, KLHL41, and KBTBD13) prevents the assembly of functional Cullin3 ubiquitination complex
thereby perturbing the protein turnover process. In the model shown here, this results in accumulation of abnormal proteins (for example,
S1, S2, S3) leading to unavailability of normal proteins in skeletal muscle leading to a diseased state.
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mutations localized in the BACK domain of the KLHL7
protein were predicted to affect the ubiquitination
complexes [57]. KLHL10 is specifically expressed in
testis and mutations of this gene lead to oligozoosper-
mia and male infertility. Missense changes in KLHL10
impair homodimerization that is required for normal
protein function, resulting in functional deficiency in
patients [58]. Spinocerebellar ataxia type 8 (SCA8) is a
dominantly inherited disorder caused by large CTG re-
peat expansions in the untranslated antisense RNA of
the KLHL1 gene [123]. While the molecular disease
mechanism is still unclear, reduction of KLHL1 in mice
leads to the degeneration of Purkinje cell function, sug-
gesting a significant role in the pathophysiology of
SCA8 [124]. Giant axonal neuropathy (GAN) is a rare
autosomal recessive progressive neurodegenerative dis-
order involving the peripheral and central nervous sys-
tems. A number of mutations in gigaxonin (GAN), a BTB-
Kelch protein, have been identified as resulting in a gener-
alized disorganization of cytoskeletal intermediate filaments
[45,125]. This cytoskeletal disorganization is attributed
to an accumulation of abnormal proteins that are nor-
mally degraded by ubiquitinin-proteasome pathway in
gigaxonin deficiency [126]. Collectively, these observa-
tions suggest that similar molecular pathways may be
involved in the pathophysiology of a variety of diseases
caused by abnormalities of Kelch proteins.
Conclusions
Recent developments in gene discovery have led to the
identification of Kelch family members as regulators of
skeletal muscle development and function. We are still
in the early stages of fully understanding the molecular
pathways regulated by these proteins. Nonetheless, the
discovery of these proteins in skeletal muscle diseases
and function is very exciting, both in terms of improving
diagnostics and opening up new directions of research
on cellular and molecular pathways crucial for skeletal
muscle function. Further studies on ubiquitination and
the identification of Kelch substrates in skeletal muscle
will help us to develop suitable therapeutics for a wide
range of muscle diseases and related disorders.
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